201 related articles for article (PubMed ID: 22682552)
1. Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
Di Sciascio G; Mangiacapra F
J Am Coll Cardiol; 2012 Jul; 60(5):378-80. PubMed ID: 22682552
[No Abstract] [Full Text] [Related]
2. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic therapy in PCI: why not heparin?
Shahzad A; Cooper RM; Stables RH
EuroIntervention; 2013 Aug; 9(4):423-6. PubMed ID: 23965346
[No Abstract] [Full Text] [Related]
4. The effect of differing pharmacologic strategies on infarct size in primary PCI--more confirmatory data for bivalirudin.
Kimmelstiel C
Catheter Cardiovasc Interv; 2012 Jun; 79(7):1090-1. PubMed ID: 22674760
[No Abstract] [Full Text] [Related]
5. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topol EJ
Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
[TBL] [Abstract][Full Text] [Related]
6. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin in acute myocardial infarction: "primum non nocere": the eternal dilemma: balancing risks and benefits in high-risk patients.
Alfonso F; Paulo M
JACC Cardiovasc Interv; 2010 Aug; 3(8):803-5. PubMed ID: 20723850
[No Abstract] [Full Text] [Related]
8. Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
Saw J; Moliterno DJ
Coron Artery Dis; 2003 Aug; 14(5):373-80. PubMed ID: 12878902
[No Abstract] [Full Text] [Related]
9. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.
Schulz S; Kastrati A; Ferenc M; Massberg S; Birkmeier KA; Laugwitz KL; Kufner S; Gick M; Dommasch M; Schühlen H; Schömig A; Berger PB; Mehilli J; Neumann FJ;
EuroIntervention; 2013 Aug; 9(4):430-6. PubMed ID: 23455033
[TBL] [Abstract][Full Text] [Related]
10. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
Dangas GD; Caixeta A; Mehran R; Parise H; Lansky AJ; Cristea E; Brodie BR; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Möeckel M; Stone GW;
Circulation; 2011 Apr; 123(16):1745-56. PubMed ID: 21482968
[TBL] [Abstract][Full Text] [Related]
11. HORIZONS-AMI.
Webster MW
Lancet; 2010 Jan; 375(9712):375. PubMed ID: 20113821
[No Abstract] [Full Text] [Related]
12. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
Parodi G; Antoniucci D; Nikolsky E; Witzenbichler B; Guagliumi G; Peruga JZ; Stuckey T; Dudek D; Kornowski R; Hartmann F; Lansky AJ; Mehran R; Stone GW
JACC Cardiovasc Interv; 2010 Aug; 3(8):796-802. PubMed ID: 20723849
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
[TBL] [Abstract][Full Text] [Related]
14. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
[TBL] [Abstract][Full Text] [Related]
15. Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.
Fiedler KA; Ndrepepa G; Schulz S; Floh S; Hoppmann P; Kufner S; Bernlochner I; Byrne RA; Schunkert H; Laugwitz KL; Kastrati A
EuroIntervention; 2016 Feb; 11(11):e1275-82. PubMed ID: 26865445
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic therapy to support primary PCI.
Morrow DA
N Engl J Med; 2008 May; 358(21):2280-2. PubMed ID: 18499573
[No Abstract] [Full Text] [Related]
17. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
Geisler T; Müller K; Karathanos A; Bocksch W; Gawaz M; Deliargyris E; Bernstein D; Lincoff AM; Mehran R; Dangas G; Stone GW
EuroIntervention; 2014 May; 10(1):97-104. PubMed ID: 24048204
[TBL] [Abstract][Full Text] [Related]
18. [Antithrombotic therapy during percutaneous coronary interventions].
Verheugt FW; Dieker H; Aengevaeren WR
Ned Tijdschr Geneeskd; 2005 Apr; 149(17):912-6. PubMed ID: 15884403
[TBL] [Abstract][Full Text] [Related]
19. Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction.
Mehilli J; Neumann FJ; Ndrepepa G; King L; Schulz S; Maimer Rodrigues da Cunha F; Jochheim D; Byrne RA; Hausleiter J; Ott I; Massberg S; Kastrati A; Pache J
Am Heart J; 2013 Apr; 165(4):537-43. PubMed ID: 23537970
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study).
Saucedo JF; Aude W; Pacheco R; Thorn B; Matin Z; Husain K; Garza L
Am J Cardiol; 2005 Jun; 95(12):1453-6. PubMed ID: 15950569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]